Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Rt-PA in the Treatment of Acute Ischemic Stroke

30 de abril de 2014 actualizado por: Boehringer Ingelheim

ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset

To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

821

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Alemania
      • Altenburg, Alemania
        • 135.312.49031 Boehringer Ingelheim Investigational Site
      • Bamberg, Alemania
        • 135.312.49011 Boehringer Ingelheim Investigational Site
      • Beeskow, Alemania
        • 135.312.49037 Boehringer Ingelheim Investigational Site
      • Bochum, Alemania
        • 135.312.49017 Boehringer Ingelheim Investigational Site
      • Frankfurt/Main, Alemania
        • 135.312.49038 Boehringer Ingelheim Investigational Site
      • Hamburg, Alemania
        • 135.312.49041 Boehringer Ingelheim Investigational Site
      • Hannover, Alemania
        • 135.312.49023 Boehringer Ingelheim Investigational Site
      • Heidelberg, Alemania
        • 135.312.49001 Boehringer Ingelheim Investigational Site
      • Köln, Alemania
        • 135.312.49008 Boehringer Ingelheim Investigational Site
      • Leipzig, Alemania
        • 135.312.49014 Boehringer Ingelheim Investigational Site
      • Ludwigshafen am Rhein, Alemania
        • 135.312.49020 Boehringer Ingelheim Investigational Site
      • Magdeburg, Alemania
        • 135.312.49004 Boehringer Ingelheim Investigational Site
      • Mainz, Alemania
        • 135.312.49003 Boehringer Ingelheim Investigational Site
      • Mannheim, Alemania
        • 135.312.49018 Boehringer Ingelheim Investigational Site
      • Minden, Alemania
        • 135.312.49002 Boehringer Ingelheim Investigational Site
      • München, Alemania
        • 135.312.49006 Boehringer Ingelheim Investigational Site
      • Siegen, Alemania
        • 135.312.49005 Boehringer Ingelheim Investigational Site
      • Teupitz, Alemania
        • 135.312.49025 Boehringer Ingelheim Investigational Site
      • Wiesbaden, Alemania
        • 135.312.49009 Boehringer Ingelheim Investigational Site
  • Austria
      • Graz, Austria
        • 135.312.43004 Boehringer Ingelheim Investigational Site
      • Innsbruck, Austria
        • 135.312.43007 Boehringer Ingelheim Investigational Site
      • Klagenfurt, Austria
        • 135.312.43010 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 135.312.43001 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 135.312.43012 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 135.312.43013 Boehringer Ingelheim Investigational Site
      • Ma.Gugging/Klosterneuburg, Austria
        • 135.312.43008 Boehringer Ingelheim Investigational Site
      • Salzburg, Austria
        • 135.312.43006 Boehringer Ingelheim Investigational Site
      • St. Pölten, Austria
        • 135.312.43003 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 135.312.43002 Boehringer Ingelheim Investigational Site
  • Bélgica
      • Aalst, Bélgica
        • 135.312.32006 O.L. Vrouwziekenhuis
      • Anderlecht, Bélgica
        • 135.312.32002 Boehringer Ingelheim Investigational Site
      • Antwerpen, Bélgica
        • 135.312.32014 Boehringer Ingelheim Investigational Site
      • Brugge, Bélgica
        • 135.312.32001 Boehringer Ingelheim Investigational Site
      • Kortrijk, Bélgica
        • 135.312.32011 Boehringer Ingelheim Investigational Site
      • Leuven, Bélgica
        • 135.312.32005 Boehringer Ingelheim Investigational Site
      • Yvoir (Godinne), Bélgica
        • 135.312.32016 Boehringer Ingelheim Investigational Site
  • Dinamarca
      • Aalborg, Dinamarca
        • 135.312.45005 Boehringer Ingelheim Investigational Site
      • Aarhus, Dinamarca
        • 135.312.45002 Boehringer Ingelheim Investigational Site
      • Copenhagen NV, Dinamarca
        • 135.312.45001 Boehringer Ingelheim Investigational Site
      • Glostrup, Dinamarca
        • 135.312.45004 Boehringer Ingelheim Investigational Site
  • Eslovaquia
      • Bratislava, Eslovaquia
        • 135.312.42103 NEURON PLUS s.r.o
      • Levoca, Eslovaquia
        • 135.312.42102 Hospital Levoca
      • Martin, Eslovaquia
        • 135.312.42104 Jessenius Faculty of Medicine Commenius University
      • Nitra, Eslovaquia
        • 135.312.42101 Faculty Hospital
      • Trnava, Eslovaquia
        • 135.312.42105 Boehringer Ingelheim Investigational Site
  • España
      • Albacete, España
        • 135.312.34019 Boehringer Ingelheim Investigational Site
      • Badalona / Barcelona, España
        • 135.312.34006 Boehringer Ingelheim Investigational Site
      • Barcelona, España
        • 135.312.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, España
        • 135.312.34002 Boehringer Ingelheim Investigational Site
      • Barcelona, España
        • 135.312.34003 Boehringer Ingelheim Investigational Site
      • Bilbao, España
        • 135.312.34011 Boehringer Ingelheim Investigational Site
      • Girona, España
        • 135.312.34007 Boehringer Ingelheim Investigational Site
      • Madrid, España
        • 135.312.34009 Boehringer Ingelheim Investigational Site
      • Madrid, España
        • 135.312.34010 Boehringer Ingelheim Investigational Site
      • Madrid, España
        • 135.312.34020 Boehringer Ingelheim Investigational Site
      • Santiago de Compostela, España
        • 135.312.34017 Boehringer Ingelheim Investigational Site
      • Sevilla, España
        • 135.312.34018 Boehringer Ingelheim Investigational Site
      • Zaragoza, España
        • 135.312.34014 Boehringer Ingelheim Investigational Site
  • Finlandia
      • Helsinki, Finlandia
        • 135.312.35801 Boehringer Ingelheim Investigational Site
      • Kuopio, Finlandia
        • 135.312.35805 Boehringer Ingelheim Investigational Site
      • Turku, Finlandia
        • 135.312.35802 Boehringer Ingelheim Investigational Site
  • Francia
      • Auch, Francia
        • 135.312.33009 Boehringer Ingelheim Investigational Site
      • Besançon cedex, Francia
        • 135.312.33016 Boehringer Ingelheim Investigational Site
      • Bordeaux cedex, Francia
        • 135.312.33013 Boehringer Ingelheim Investigational Site
      • Bourg en Bresse, Francia
        • 135.312.33017 Boehringer Ingelheim Investigational Site
      • Dijon cedex, Francia
        • 135.312.33008 Boehringer Ingelheim Investigational Site
      • Grenoble cédex 9, Francia
        • 135.312.33014 Boehringer Ingelheim Investigational Site
      • Lille cedex, Francia
        • 135.312.33015 Boehringer Ingelheim Investigational Site
      • Limoges cedex 1, Francia
        • 135.312.33019 Boehringer Ingelheim Investigational Site
      • Lyon Cedex, Francia
        • 135.312.33001 Boehringer Ingelheim Investigational Site
      • Mantes la Jolie, Francia
        • 135.312.33024 Boehringer Ingelheim Investigational Site
      • Meaux, Francia
        • 135.312.33021 Boehringer Ingelheim Investigational Site
      • Montpellier, Francia
        • 135.312.33002 Boehringer Ingelheim Investigational Site
      • Nancy, Francia
        • 135.312.33004 Boehringer Ingelheim Investigational Site
      • Nice cedex 1, Francia
        • 135.312.33003 Boehringer Ingelheim Investigational Site
      • Paris, Francia
        • 135.312.33006 Boehringer Ingelheim Investigational Site
      • Paris cedex 18, Francia
        • 135.312.33007 Boehringer Ingelheim Investigational Site
      • Pau cedex, Francia
        • 135.312.33020 Boehringer Ingelheim Investigational Site
      • Perpignan cedex, Francia
        • 135.312.33018 Boehringer Ingelheim Investigational Site
      • Pontoise, Francia
        • 135.312.33023 Boehringer Ingelheim Investigational Site
      • Saint Herblain, Francia
        • 135.312.33010 Boehringer Ingelheim Investigational Site
      • Toulouse cedex 9, Francia
        • 135.312.33005 Boehringer Ingelheim Investigational Site
      • Toulouse cedex 9, Francia
        • 135.312.33012 Boehringer Ingelheim Investigational Site
      • Tours cedex 9, Francia
        • 135.312.33011 Boehringer Ingelheim Investigational Site
      • Versailles, Francia
        • 135.312.33022 Boehringer Ingelheim Investigational Site
  • Grecia
      • Athens, Grecia
        • 135.312.30004 Boehringer Ingelheim Investigational Site
      • Larissa, Grecia
        • 135.312.30005 Boehringer Ingelheim Investigational Site
      • Thessaloniki, Grecia
        • 135.312.30002 Boehringer Ingelheim Investigational Site
  • Hungría
      • Debrecen, Hungría
        • 135.312.36002 University of Debrecen
      • Györ, Hungría
        • 135.312.36001 Aladár Petz County Hospital
      • Miskolc, Hungría
        • 135.312.36006 BAZ County and Teaching Hospital
  • Italia
      • Coppito (aq), Italia
        • 135.312.39020 Università degli Studi
      • Firenze, Italia
        • 135.312.39013 A. O. Universitaria di Careggi
      • Firenze, Italia
        • 135.312.39019 Ospedale Santa Maria Annunziata
      • Imperia, Italia
        • 135.312.39022 Ospedale di Imperia
      • Milano, Italia
        • 135.312.39024 Istituto Scientifico San Raffaele
      • Padova, Italia
        • 135.312.39002 A. O. di Padova - Policlinico Universitario
      • Perugia, Italia
        • 135.312.39005 A. O. di Perugia - Policlinico Monteluce
      • Piacenza, Italia
        • 135.312.39023 P. O. di Piacenza
      • Pietra Ligure (sv), Italia
        • 135.312.39016 A. O. Ospedale Santa Corona
      • Pisa, Italia
        • 135.312.39006 Ospedale Santa Chiara
      • Reggio Emilia, Italia
        • 135.312.39003 A. O. Arcispedale "Santa Maria Nuova"
      • Roma, Italia
        • 135.312.39001 A. O. Policlinico Umberto I
      • Roma, Italia
        • 135.312.39025 Università di Roma "La Sapienza"
      • Udine, Italia
        • 135.312.39018 Ospedale S. Maria della Misericordia
      • Verona, Italia
        • 135.312.39009 Ospedale Maggiore di BorgoTrento
      • Vicenza, Italia
        • 135.312.39004 Ospedale Civile
  • Noruega
      • Bergen, Noruega
        • 135.312.47001 Boehringer Ingelheim Investigational Site
      • Trondheim, Noruega
        • 135.312.47003 Boehringer Ingelheim Investigational Site
      • Tønsberg, Noruega
        • 135.312.47006 Boehringer Ingelheim Investigational Site
  • Países Bajos
      • Amsterdam, Países Bajos
        • 135.312.31001
      • Enschede, Países Bajos
        • 135.312.31007 Medisch Spectrum Twente
  • Polonia
      • Gdansk, Polonia
        • 135.312.48004 Medical University of Gdansk
      • Katowice, Polonia
        • 135.312.48005 Dept. of Neurology, Regenerative and Cerebrovascular Disease
      • Opole, Polonia
        • 135.312.48006 Wojewodship Specialistic Neuropsychiatric Centre in Opole
      • Warsaw, Polonia
        • 135.312.48001 Institute of Psychiatry & Neurology in Warsaw
      • Warsaw, Polonia
        • 135.312.48002 Dr. Anna Gostynska Wolski Hospital
  • Portugal
      • Coimbra, Portugal
        • 135.312.35101 Hospitais da Universidade de Coimbra
      • Lisboa, Portugal
        • 135.312.35106 Hospital de Santa Maria
      • Porto, Portugal
        • 135.312.35102 Hospital de Santo António
      • Santa Maria da Feira, Portugal
        • 135.312.35105 Hospital de São Sebastião, EPE
  • Reino Unido
      • Aberdeen, Reino Unido
        • 135.312.44025 Boehringer Ingelheim Investigational Site
      • Bournemouth, Reino Unido
        • 135.312.44002 Boehringer Ingelheim Investigational Site
      • Cambridge, Reino Unido
        • 135.312.44023 Boehringer Ingelheim Investigational Site
      • Dundee, Reino Unido
        • 135.312.44026 Boehringer Ingelheim Investigational Site
      • Glasgow, Reino Unido
        • 135.312.44003 Boehringer Ingelheim Investigational Site
      • Glasgow, Reino Unido
        • 135.312.44006 Boehringer Ingelheim Investigational Site
      • Glasgow, Reino Unido
        • 135.312.44024 Boehringer Ingelheim Investigational Site
      • Liverpool, Reino Unido
        • 135.312.44018 Boehringer Ingelheim Investigational Site
      • London, Reino Unido
        • 135.312.44030 Boehringer Ingelheim Investigational Site
  • República Checa
      • Ostrava, República Checa
        • 135.312.42001 Boehringer Ingelheim Investigational Site
      • Ostrava-Vitkovice, República Checa
        • 135.312.42004 Boehringer Ingelheim Investigational Site
      • Prague 5, República Checa
        • 135.312.42002 Boehringer Ingelheim Investigational Site
  • Suecia
      • Lidköping, Suecia
        • 135.312.46007 Boehringer Ingelheim Investigational Site
      • Malmö, Suecia
        • 135.312.46003 Boehringer Ingelheim Investigational Site
      • Skövde, Suecia
        • 135.312.46005 Boehringer Ingelheim Investigational Site
      • Stockholm, Suecia
        • 135.312.46002 Boehringer Ingelheim Investigational Site
      • Stockholm, Suecia
        • 135.312.46004 Boehringer Ingelheim Investigational Site
  • Suiza
      • Aarau, Suiza
        • 135.312.41003 Boehringer Ingelheim Investigational Site
      • Basel, Suiza
        • 135.312.41001 Boehringer Ingelheim Investigational Site
      • Lausanne, Suiza
        • 135.312.41004 Boehringer Ingelheim Investigational Site
      • St. Gallen, Suiza
        • 135.312.41002 Boehringer Ingelheim Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Female or male inpatients
  • Age: 18 - 80 years.
  • Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
  • Onset of symptoms between 3 and 4 hours prior to initiation of administration of study drug.
  • Stroke symptoms are to be present for at least 30 minutes and have not significantly improved before treatment. Symptoms must be distinguishable from an episode of generalized ischemia (i.e. syncope), seizure, or migraine disorder.
  • Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating country.
  • Patients who are unable to sign but who are able to understand the meaning of participation in the study may give an oral witnessed informed consent. These patients have to make clear undoubtfully that they are willing to participate voluntarily and must be able to understand an explanation of the contents of he information sheet.
  • Willingness and ability to comply with the protocol.

Exclusion Criteria:

  • Evidence of intracranial hemorrhage (ICH) on the CT-scan.
  • Symptoms of ischaemic attack began more than 4 hours and 30 minutes prior to infusion start or when time of symptom onset is unknown.
  • Minor neurological deficit or symptoms rapidly improving before start of infusion.
  • Severe stroke as assessed clinically (e.g. NIHSS>25) and/or by appropriate imaging techniques.
  • Epileptic seizure at onset of stroke
  • Symptoms suggestive of subarachnoid haemorrhage, even if the CT-scan is normal.
  • Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory
  • History of prior stroke and concomitant diabetes. * Prior stroke within the last 3 months
  • Platelet below 100,000/mm3. * Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, or aggressive management (IV medication) necessary to reduce BP to these limits.
  • Blood glucose <50 or > 400 mg/dl (< 2.77 or > 22.15 mmol / l). * Known haemorraghic diathesis
  • Patients receiving oral anticoagulants. * Manifest or recent severe or dangerous bleeding
  • Known history of or suspected intracranial haemorrhage
  • Suspected subarachnoid haemorrhage or condition after subarachnoid haemorrhage from aneurysm
  • History of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
  • Haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy)
  • Recent (less than 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture.
  • bacterial endocarditis, pericarditis.* Acute pancreatitis
  • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial- aneurysm, arterial/venous malformation
  • Neoplasm with increased bleeding risk

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
modified Rankin scale (mRS) 0-1 (favourable outcome) at Day 90
Periodo de tiempo: at day 90
at day 90

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Global outcome of four neurologic and disability scores combined
Periodo de tiempo: at day 90
at day 90

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Boehringer Ingelheim

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de abril de 2003

Finalización primaria (Actual)

1 de febrero de 2008

Fechas de registro del estudio

Enviado por primera vez

9 de septiembre de 2005

Primero enviado que cumplió con los criterios de control de calidad

9 de septiembre de 2005

Publicado por primera vez (Estimar)

12 de septiembre de 2005

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

16 de mayo de 2014

Última actualización enviada que cumplió con los criterios de control de calidad

30 de abril de 2014

Última verificación

1 de abril de 2014

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 135.312

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Accidente cerebrovascular

Buscar ensayos similares

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

CROs by country

CROs in Tanzania

Condiciones

Enfermedades Raras

Intervenciones de drogas

Suplementos dietéticos

Patrocinador / Colaboradores

Localizaciones

3
Suscribir